Tirzepatide

FDA Approved

Tirzepatide (LY3298176)

Aliases
Mounjaro, Zepbound, LY3298176
Administration
Subcutaneous injection (once weekly)

Documented side effects

Tier 1 · Peer-reviewed / regulatory

Nausea

A common digestive side effect, often most noticeable when starting or increasing the dose.

Vomiting

A gastrointestinal side effect that can accompany nausea, particularly early in treatment.

Diarrhea

A gastrointestinal side effect commonly reported with this class of compound.

Rare pancreatitis risk

A small but serious risk of pancreas inflammation exists with this class of compound.